New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Investing.com -- Genmab (NASDAQ: GMAB) has unveiled new data for its cancer drug Rina-S, which is being tested for use in endometrial cancer. This follows promising early results from trials in ...

NANTES, France – June 2, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the “off-the-shelf” neo-epitope-based therapeutic ...

Global mRNA Cancer Vaccines Clinical Trials, Market Trends By Indication, Development Priority Status and Market Opportunity ...

Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 ...

DFS at 24 months improved from 79% with observation to 96% with the use of a 14-gene assay to guide decision making about ...

Tens of thousands of patients with lung and breast cancer are to benefit from a “revolutionary” blood test on the NHS across England which can speed up access to targeted therapy. The new ‘liquid ...

The screening—known as a liquid biopsy—is being rolled out to around 15,000 patients with suspected lung cancer, NHS England ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...